Abstract. Rho GTPases control a wide range of cellu lar processes and contribute to tumor invasion and metastasis. As a regulator of Rho activity, ARHGDIA is aberrantly expressed in several types of tumors and plays different roles in the tumor process. To elucidate the role of ARHGDIA in HCC, we investigated the patterns of its expression, prognosis and clinical profiles in HCC. Functional assays were performed to investigate whether the alteration of ARHGDIA has an effect on cell growth, migration and invasion, as well as the status of Rho GTPases. We found that ARHGDIA was frequently downregulated in HCC and associated with tumor invasion and metastasis. Moreover, ARHGDIA was significantly associated with OS and TTR of HCC patients. Low level of ARHGDIA exhibited a decreased postoperative OS and a shorter TTR compared those with high levels. Functional assays showed that loss of ARHGDIA promoted HCC cell migration and invasion in vitro and lung metastasis formation in vivo. We found that loss of ARHGDIA significantly induced Rac1 and RhoA activation which may contribute to invasion and metastasis of HCC. In conclusion, the present study has identified loss of ARHGDIA contributed to the processes of hepatic tumorigenesis, in particular invasion and metastasis which may provide a potential therapeutic target for HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common human cancers in the world, including China (1) . It ranks as the second leading cause for cancer death worldwide. As far as great advances in the treatment of the disease is concerned, prognosis for HCC patients is not favorable due to the likelihood of intrahepatic and extrahepatic recurrence, which leads to a high mortality rate (2, 3) . Therefore, investigations into the molecular mechanisms involving in HCC metastasis have major importance to develop novel avenues for targeted therapies.
Cell motility plays an important role in tumor invasion and metastasis. Rho GTPases regulate actin polymerization, actomyosin contractility and microtubule dynamics controlling a wide range of cellu lar processes, including cell adhesion, and migration. They function as molecular switches in cell signaling, alternating between inactive GDP-bound states and active GTP-bound states. The active-GTP form of Rho is governed by a panel of inhibitors including ARHGDIs which block activation of Rho proteins by sequestering the GDP-bound Rho proteins in the cytosol (4) . ARHGDIs includes three members, named ARHGDIA, ARHGDIB and ARHGDIG. ARHGDIA is ubiquitously expressed and interacts with several Rho GTPases, including RhoA, Rac1 and Cdc42 (5, 6) . As a regulator of Rho activity, ARHGDIA has attracted increasing attention. There are studies showing that ARHGDIA is aberrantly expressed in many tumors and plays an important role in the tumor process. However, the role of ARHGDIA in HCC remains to be unraveled. In this study, we found that ARHGDIA was frequently downregulated in HCC and significantly associated with prognosis of HCC patients. Loss of ARHGDIA promoted HCC cells invasion and metastasis in vitro and in vivo, which might be due to Rac1 and RhoA GTPase activation induced by silencing ARHGDIA.
Materials and methods
Patients and specimens. A total of 86 patients were enrolled in the present study. The patients did not receive any preoperative cancer treatment and their follow-up data were available. They were followed-up after surgical treatment until May 2011, with a median follow-up of 29 months (range 2-73. 2 months). During the follow-up, the patients were monitored every 2-3 months as described previously (7) . CT scanning or MRI was performed when tumor recurrence was suspected. The recurrent tumors were treated as described Colony formation assay. The 500 cells were plated into 6-well culture-plates and cultured for 14 days to allow colony formation. Colonies were stained with 0.1% crystal violet (Amersco, Solon, OH, USA) in 50% methanol and 10% glacial acetic acid for counting.
In vitro migration and invasion assays. For the migration assays, 2x10 4 cells were added into the upper chamber of the insert with the non-coated membrane (Millipore, 8-mm pore size). For the invasion assays, each well insert was layered with 50 µl of a 1:4 mixture of Matrigel/Dulbecco's minimal essential medium (BD Bioscience). Cells (1x10 5 ) were added into the upper chamber of the insert. In both assays, cells were plated in medium without serum, and medium containing 10% FBS in the lower chamber served as chemoattractant. After several hours of incubation, the cells that did not migrate or invade through the pores were carefully wiped out with cotton swab. Cells on the lower surface of the membrane were fixed with methanol and stained with Giemsa and counted. Each experiment was performed in triplicates.
In vivo metastasis assays. For in vivo metastasis assays, SMMC-7721 cells infected with either the ARHGDIA-siRNAs or the vector were transplanted into nude mice (5-week-old BALB/c-nu/nu, 6 per group, 2x10
6 cells for each mouse) through the tail vein. After 6 weeks, mice were sacrificed. The lungs were removed, fixed in formalin, and embedded in paraffin. Consecutive sections of the whole lung were subjected to hematoxylin and eosin staining. All of the metastatic foci in lung were calculated microscopically to evaluate the development of pulmonary metastasis. The lung metastases were calculated and evaluated independently by two pathologists.
Western blotting. Equal amounts of protein were resolved by 10% SDS-polyacrylamide gel electrophoresis and transblotted onto nitrocellulose membrane (Bio-Rad). After blocking in 5% non-fat milk, the membranes were incubated with rabbit anti-ARHGDIA antibody (mAb; 1:1,000; Epitomics), rabbit anti-Rac1 antibody (mAb; 1:1,000; Epitomics), rabbit anti-RhoA antibody (mAb; 1:1,000; Epitomics), rabbit anti-Cdc42 antibody (mAb; 1:1,000; Epitomics) or rabbit anti-GAPDH mAb (1:5,000; Epitomics). The proteins were detected with enhanced chemiluminescence reagents (Pierce).
Immunoprecipitation of active Cdc42, RhoA, Rac1. The protocol used was based on the availability of a mouse monoclonal antibody directed against the active form of Cdc42, RhoA and Rac1 commercially through NewEast Biosciences (Malvern, PA, USA). Cells were lysed in 1 ml of ice-cold lysis buffer for 10 min. Aliquots of each cell lysate were added to two microcentrifuge tubes, one for analysis of the active and the other for the analysis of total potein content. Then 1 µl of anti-active Cdc42, RhoA or Rac1 monoclonal antibody was added, as well as 20 µl of Dynabead Protein G added, and samples were incubated overnight with rotation at 4˚C. Beads were pelleted by centrifugation for 1 min at 5,000 g, then washed three times with 0.5 ml of lysis buffer, resuspended in 20 µl of 2X reducing SDS-PAGE sample buffer, heated at 100˚C for 5 min, then separated on 12% polyacrylamide gels and processed for western blotting after transferring to PVDF membranes. Rabbit polyclonal antibody against total Cdc42, RhoA and Rac1 (mAb; 1:1,000; Epitomics) was used for western blotting.
Statistical analysis. Statistical analysis was performed with SPSS 15.0 (SPSS Inc, Chicago, IL, USA) and values are expressed as the mean ± standard deviation. The differences between groups were analyzed using Student's t-test (only two groups), or one-way analysis of variance (more than two groups were compared). P<0.05 was considered statistically significant.
Results

ARHGDIA is frequently downregulated in HCC and associated with tumor invasion and metastasis.
The protein levels of ARHGDIA in 86 cases of HCC patient samples and corresponding non-cancer liver tissues (40 cases) were measured by immunohistochemical staining. Strong staining of ARHGDIA was observed in adjacent non-cancer liver tissue, but weaker in more than half (65%) of the HCC tissues (Fig. 1A) . The expression level is significantly downregulated in HCC compared with non-cancer liver tissues (P<0.001) (Fig. 1B) . At various regions of tumor within the same slide, it appeared that ARHGDIA expression remarkably decreased at invasive cancer in situ such as tumor embolus. Next, we analysed the relationships between ARHGDIA and clinical pathological features of HCC. Significant correlations were observed between ARHGDIA and vascular invasion (tumor invasion in blood vessel or bile duct) (P=0.0216). Low level of ARHGDIA expression was observated in 79.07% of vascular invasion group (Table I ). The result indicated that ARHGDIA might correlated with HCC metastasis. Then, the ARHGDIA level was analyzed in a panel of human HCC cell lines with different metastatic potential. The level of ARHGDIA in the high-metastatic HCC cell lines (MHCC-97H) was much lower than that in the less-metastatic HCC cell lines (Huh-7, SMMC-7721) (Fig. 3C) , indicating that the downregulation of ARHGDIA was related to the metastatic ability of HCC.
The association of ARHGDIA with prognosis of HCC patients. In the Kaplan-Meier analyses, the expression level of ARHGDIA was significantly associated with OS and TTR. The patients with low level of ARHGDIA exhibited a decreased postoperative OS and a shorter TTR compared those with high level (Fig. 2) . The 1-, 3-and 5-year OS rates of the patients with low level were 74.8, 42.2 and 36.6%, respectively, which were significantly lower than those with high level group (86.9, 65.4 and 51.5%, respectively; P=0.017). The 1-, 3-and 5-year cumulative recurrence rates of low level group were 37.8, 63.9 and 75.6%, respectively, which were significantly higher than those of the high level group (20.5, 47.2 and 60.4%, respectively; P=0.012).
ARHGDIA has no effect on HCC cell proliferation or the colony formation ability. To explore the functions of ARHGDIA in HCC, specific siRNAs against ARHGDIA were exploited to knockdown expression in SMMC-7721, and Huh-7 cell lines. As shown in Fig. 3D , siRNA significantly reduced the expression of ARHGDIA protein. We also constructed a lentivirus vector expressing ARHGDIA and established the stable cell line MHCC-97H, which has low basal levels of ARHGDIA (Fig. 3E) . In cell proliferation assays, knocking down ARHGDIA showed no obvious impact on the proliferation of SMMC-7721 and Huh-7 cells (Fig. 3A) . Similarly, overexpression of ARHGDIA did not affect MHCC-97H cell growth either (Fig. 3B) . Next, the colony formation assays were performed to observe the effects of ARHGDIA on the anchoring growth ability of HCC cells. No obvious effects were observed on the colony formation ability of HCC cells after infection with ARHGDIA-siRNAs or lenti-ARHGDIA (Fig. 4) .
Loss of ARHGDIA promotes HCC cell invasion and metastasis in vitro and in vivo.
Given that expression of ARHGDIA is highly associated with the metastatic property of HCC, we wondered whether ARHGDIA could play an important role in HCC cell invasion and metastasis. Transwell assays without Matrigel demonstrated that downregulation of ARHGDIA could significantly promote migration of Huh-7 and SMMC-7721 cells when compared with vector groups (Fig. 5A ). Transwell assays with Matrigel showed that the invasive capacities were dramatically enhanced in these two stable cell lines when compared with the control cells (Fig. 5B) . However, the migration and invasion of MHCC-97H cells decreased when ARHGDIA was upregulated (Fig. 5) . These results indicated that loss of ARHGDIA could significantly enhance HCC cell migration and invasion in vitro. To further explore the role of ARHGDIA in tumor metastasis in vivo, SMMC-7721 cells infected with si-ARHGDIA were transplanted into nude mice through the tail vein. Interestingly, the number of the metastatic nodules in the lung were dramatically increased in si-ARHGDIA groups compared with vector control (P=0.0377) (Fig. 6 ). Taken together, these observations suggested that ARHGDIA is a negative metastatic regulator for HCC.
Loss of ARHGDIA significantly increases the activities of Rac1 and RhoA GTPases in HCC cells.
Regulation of the cytosol-membrane cycling of the Rho GTPase by ARHGDIs has a major role in controlling Rho GTPase activity and function. Given the important role of ARHGDIA in HCC cell migration and invasion, we conducted immunoprecipitation assays to determine the status of Rho GTPases in HCC cells. The mouse monoclonal antibody directed against Table I . Expression of ARHGDIA detected by IHC and the clinicopathologic features of HCC patients (n=86). the active form of Cdc42, RhoA and Rac1 were used in the immunoprecipitation assays. The results indicated that loss of ARHGDIA significantly induced RhoA and Rac1 activation in SMMC-7721 cells (Fig. 7A) , particularly the activity of RHOA increased nearly 4-fold compared to the control. The Cdc42 activity was also slightly increased, but did not reach statistical significance (Fig. 7B) . Numerous studies have confirmed that activation of signaling of Rho GTPases plays an important role in cancer progression and metastasis (9) . Therefore, the activation of Rho GTPase proteins induced by silencing ARHGDIA might contribute to tumor invasion and metastasis of HCC. 
ARHGDIA expression ------------------------------------------
Discussion
Changes in ARHGDIA expression levels have been associated with many cancers (10) . Previous studies indicated that the changes vary depending on the tumor type. For instance, ARHGDIA expression is upregulated in colorectal and ovarian cancers, and high expression levels correlate with increased invasion and resistance to chemotherapy (11) (12) (13) . By contrast, ARHGDIA expression is reduced in brain cancers, and inversely correlate with the degree of malignancy (14) . In breast cancers, Jiang et al found a significant reduction of ARHGDIA expression in tumor versus normal breast (15) . Furthermore, the reduction of ARHGDIA had a significant, poor prognostic correlation when tumors were stratified by node status or by recurrence and disease-specific death. Therefore, the effects of the ARHGDIA on cancers are complex and context-dependent. In the present study, we first clarified the role of ARHGDIA in HCC to ensure that ARHGDIA is indeed a tumor suppressor gene involved in HCC invasion and metastasis. We found the following evidence: a) ARHGDIA was frequently downregulated in HCC compared with noncancer liver tissues. Within the same IHC slide, ARHGDIA expression remarkably decreased at invasive cancer in situ such as tumor embolus. b) ARHGDIA expression level was significantly associated with vascular invasion. HCC with vascular invasion had a lower ARHGDIA expression than those without vascular invasion. c) The level of ARHGDIA in the high-metastatic HCC cell lines was lower than that in the low-metastatic cell lines. d) In the Kaplan-Meier analyses, the expression level of ARHGDIA was significantly associated with OS and TTR. The patients with low level of ARHGDIA exhibited a decreased postoperative OS and a shorter TTR.
e) The functional assay indicated that in vitro and in vivo phenotypes of ARHGDIA correlated well with the patterns of its expression and prognosis in HCC, as well as clinical profiles. Loss of ARHGDIA could promote HCC cell migration and invasion in vitro and increase lung metastasis in vivo. Therefore, the evidence above proves that ARHGDIA is a tumor suppressor and plays an important role in HCC progression especially in invasion and metastasis. The changes in ARHGDIA expression are manifested through their actions on multiple RHO GTPases, and the levels and activi ty vary significantly in the different cell types and cancers. A single Rho family member can have opposite effects in different tumor types (16, 17) , possibly leading to the biological diversity of ARHGDIA. Many experiments have reported that loss of ARHGDIA might reduce inhibition on endogenous Rho family GTPases exerting a negative regulator of Rho-family GTPase activity. Turner et al found that the amount of RhoGTP increased significantly in the HEL cells transfected with ARHGDIA siRNA (18) . In ARHGDIA-knockout mice, renal abnormality is associated with increased Rac1 (but not RhoA) (19) , while the abnormal basal permeability of the pulmonary vascular endothelium correlates with the increasing activity of RhoA (20) . On the contrary, overexpression of ARHGDIA significantly inhibits the activities of RhoA, Rac1, Cdc42 and reduces the positioning of these active proteins in membranes of myocardial cells (21) . In HCC, we confirmed that loss of ARHGDIA significantly induced Rac1, RhoA activation in SMMC-7721 cells. Numerous studies indicate that deregulated signaling of Rho GTPases plays an important role in HCC progression and metastasis (9) . RhoA pathway associates with venous invasion, cell differentiation and poor prognosis (22) , correlating with tumor progression and metastasis (23) (24) (25) . Rac1 GTPase is crucial for actin cytoskeleton reorganization at the cell cortex and is involved in processes of HCC migration and invasion (26) (27) (28) (29) . Therefore, activating Rho GTPase initiated by silencing ARHGDIA in HCC cells may at least in part mediate the effect of tumor invasion and metastasis.
In conclusion, the present study identified ARHGDIA as a suppressor of HCC invasion and metastasis by the RhoGTP pathway. The above findings may contribute to better understanding of the processes of hepatic tumorigenesis, especially invasion and metastasis thus providing a potential therapeutic target in HCC. 
